公开(公告)号：ZA202000803B

公开(公告)日：2021-08-25

申请号：ZA202000803

申请日：2020-02-07

Applicant: UCB BIOPHARMA SRL

Inventor： RALPH ADAMS ,  THOMAS ALLEN CESKA ,  ANNA MARIE DAVIES ,  ALISTAIR JAMES HENRY ,  XIAOFENG LIU ,  JAMES MICHAEL MCDONNELL ,  BRIAN JOHN SUTTON ,  MARTA KATARZYNA WESTWOOD

Abstract: The present invention relates to the area of improved anti-IgE antibodies and antigen binding agents, and compositions thereof, which target IgE, for instance: for use in treating disorders caused by IgE (such as allergic responses, or certain autoimmune responses); and, in particular, disorders caused by the interaction of IgE with the FcεRI receptor. In particular, this invention relates to improved anti-IgE antibodies and antigen binding agents related to novel mutants of omalizumab (Xolair®). The improved anti-IgE antibodies and antigen binding agents of the invention may have improved affinity for IgE and/or an improved interaction with the Cε2 domain of IgE and/or an improved modified epitope on IgE (for instance further involving the Cε2 domain of IgE) and/or the ability to disassociate IgE from the FcεRI receptor for instance at pharmaceutically-relevant concentrations. In one aspect, improved or novel treatments for IgE mediated disorders are disclosed in which IgE is targeted (for instance free IgE and/or IgE complexed with the FcεRI receptor).

公开(公告)号：BR112020025510A2

公开(公告)日：2021-03-09

申请号：BR112020025510

申请日：2019-06-20

Applicant: UCB BIOPHARMA SRL

Inventor： ALISTAIR JAMES HENRY ,  GIANCARLO TRANI ,  GREGORY WILLIAM HASLETT ,  JAMES MADDEN ,  JUDI CHARLOTTE NEUSS ,  KONSTANTINOS RAMPALAKOS ,  MATTHEW DUNCAN SELBY ,  OLIVER PHILPS ,  PRAFULKUMAR TULSHIBHAI CHOVATIA ,  RICHARD JEREMY FRANKLIN ,  RICKKI LEE CONNELLY ,  SUGANTHAN SELVARATNAM ,  TIMOTHY JOHN NORMAN ,  WILLIAM ROSS PITT ,  ZHAONING ZHU

IPC: C07D333/68 ,  A61K31/381 ,  A61P11/06 ,  A61P37/08 ,  C07D333/66 ,  C07D333/78 ,  C07D409/04 ,  C07D409/06 ,  C07D409/12 ,  C07D409/14 ,  C07D413/04 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D487/04 ,  C07D495/04 ,  C07D495/10 ,  C07D498/10

Abstract: derivados de tiofeno da fórmula (i) e um sal do mesmo farmaceuticamente aceitável são providos. estes compostos têm utilidade para o tratamento ou prevenção de distúrbios causado pela ige, tais como alergia, hipersensibilidade tipo 1 ou inflamação sinusal familiar.